Research team

Expertise

-Neuroimaging and neurophysiology expertise in human participants (healthy and patient populations) -Computational modelling of internal representations of knowledge in the human brain - Artificial intelligence for diagnostic use in the Memory Clinic

Neurophysiological Markers of Cognition in Healthy Ageing & Neurodegeneration. 01/10/2022 - 30/09/2026

Abstract

Early and reliable diagnosis of neurodegenerative diseases such as Alzheimer's Disease (AD) and Frontotemporal Degeneration (FTD) is paramount from a clinical point of view, to provide accurate information about the cause of a patient's symptoms and their prognosis. Fluid- and PET-based biomarkers are reliable tools for early diagnosis of AD, but they entail invasive, costly procedures and are not easily accessible to all clinicians. Here, we advocate the development of a new and reliable neurophysiological marker as a suitable triage tool to identify patients with cognitive complaints who are at high risk for AD or FTD. Functional changes, which can be measured using high-density Electroencephalography (hd-EEG), precede structural changes of the brain. Our focus is on characterizing functional changes related to higher-order cognitive abilities which are relevant for the activities of daily living such as mental flexibility, reasoning and communication. We here introduce a novel hd-EEG approach to assess the early functional changes at the individual level. Studying neurophysiological changes at the individual level is necessary for clinical implementation, where markers need to be reliable at the single-patient level. Theoretically, the impact of interindividual differences on cognitive decline has received much attention in the past decade. The concept of cognitive reserve reflects the flexibility of cognitive processes that helps to explain the differential susceptibility of day-to-day-function to the effects of neurodegenerative diseases on the brain. Fluid intelligence (correlating with one's capacity for mental flexibility and reasoning) has been proposed as a proxy for cognitive reserve. In this proposal, we will acquire hd-EEG during paradigms testing fluid intelligence and language in a cohort of patients with neurodegenerative disease (biomarker-proven AD, and non-AD pathologies such as FTD) as well as controls. We previously demonstrated in older adults that larger task-related neurophysiological signal changes measured using magnetoencephalography are linked to better cognitive performance. In this project, we validate our approach using hd-EEG and test whether we can identify patients with neurodegenerative disease using single-case statistics to validate our neurophysiological marker for use in clinical practice. The scientific innovation of this project firstly lies in the translation of recent discoveries in cognitive neuroscience to clinical practice for use at the level of a single individual, combined with methodological advances regarding the acquisition and analysis of hd-EEG. Our goal is ultimately to optimize the clinical diagnostic pathway for neurodegeneration, by identifying some individuals as low-risk and providing reassurance to these patients, while prioritizing patients with a high risk of neurodegeneration for more invasive diagnostic procedures. In the future, neurophysiological markers could help to efficiently identify individuals who may benefit from disease-modifying therapy in a clinical trial.

Researcher(s)

Research team(s)

Project type(s)

  • Research Project

Collen-Francqui Start-up Grant (Rose Bruffaerts). 01/10/2022 - 30/09/2025

Abstract

Early and reliable diagnosis of neurodegenerative diseases such as Alzheimer's Disease (AD) and Frontotemporal Degeneration (FTD) is paramount from a clinical point of view, to provide accurate information about the cause of a patient's symptoms and their prognosis. Fluid- and PET-based biomarkers are reliable tools for early diagnosis of AD, but they entail invasive, costly procedures and are not easily accessible to all clinicians. Here, we advocate the development of a new and reliable neurophysiological marker as a suitable triage tool to identify patients with cognitive complaints who are at high risk for AD or FTD. Functional changes, which can be measured using high-density Electroencephalography (hd-EEG), precede structural changes of the brain. In this proposal, we examine hd-EEG in a cohort of patients with neurodegenerative disease (biomarker-proven AD, and non-AD pathologies such as FTD) as well as controls. We previously demonstrated in older adults using multivariate analysis that larger task-related neurophysiological signal changes measured using magnetoencephalography are linked to better cognitive performance. In this project, we validate our approach using hd-EEG and we will develop a multivariate marker reflecting the dynamic neural pattern across the whole brain at the individual level. Using this "neural fingerprint" we test whether we can identify patients with neurodegenerative disease using single-case statistics to validate our multivariate neurophysiological marker for use in clinical practice. The scientific innovation of this project firstly lies in the translation of recent discoveries in cognitive neuroscience to clinical practice for use at the level of a single individual, combined with methodological advances regarding the acquisition and analysis of hd-EEG. Our goal is ultimately to optimize the clinical diagnostic pathway for neurodegeneration, by identifying some individuals as low-risk and providing reassurance to these patients, while prioritizing patients with a high risk of neurodegeneration for more invasive diagnostic procedures. In the future, neurophysiological markers could help to efficiently identify individuals who may benefit from disease-modifying therapy in a clinical trial.

Researcher(s)

Research team(s)

Project type(s)

  • Research Project

Research on Alzheimer's Disease and other neurodegenerative disorders: development of non-invasive markers of speech and language 01/01/2022 - 31/12/2023

Abstract

Language impairment often occurs early during the course of neurodegenerative diseases such as Alzheimer's Disease and Frontotemporal Degeneration and severly impacts quality of life. Markers of speech and language may provide non-invasive and low-cost measures that could help diagnose and monitor neurodegenerative disorders. However, the clinical implementation of such markers is at present limited due to several challenges. First, some of these markers may prove language-specific and second, characterizing these markers can be time-consuming. Previously, we have demonstrated that some specific pathological patterns found in patients with Frontotemporal Degeneration (FTD) in Dutch, were similar to what has been observed in patients with FTD in English and German. In this pilot project in close collaboration with GENFI (the Genetic FTD Initiative), we further develop pen-and-paper tests and derive speech and language markers from connected speech in Dutch. We will identify markers that have the potential to generalize across different languages. Our goal is to characterize speech and language impairment in detail across different neurodegenerative diseases and provide clinically useful tools to improve patient care.

Researcher(s)

Research team(s)

Project type(s)

  • Research Project